

Substitute form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/008,062	
			Filing Date	October 19, 2001	
			First Named Inventor	David Rizzoli	
			Group Art Unit	1819 1642	
			Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	5405.252



RECEIVED
MAY 12 2003

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
aml	1	RE38,008		Abrams et al.	02/25/2003	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T

Examiner Signature	<i>aml</i>	Date Considered	03/23/2005
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1

Complete if Known

Application Number	10/008,062
Filing Date	10/19/2001
First Named Inventor	David A. Rizzieri
Group Art Unit	1642
Examiner Name	Alana M. Harris
Attorney Docket Number	5405-252

Sheet	1	of	1
-------	---	----	---

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

OTHER NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T
amv	1.	Bartsch, <i>The Extracellular Matrix Molecule Tenascin-C: Expression In Vivo and Functional Characterization In Vitro</i> , Progress in Neurobiology, 49 :145-168 (1996)		
↓	2.	Hibino et al., <i>Tenascin Suppresses CD3-Mediated T Cell Activation</i> , Biochemical and Biophysical Research Communications, 250 :119-124 (1998)		
	3.	Latijnhouwers, et al., <i>Tenascin Expression During Wound Healing in Human Skin</i> , Journal of Pathology, 178 :30-35 (1996)		
	4.	Zhou et al., <i>Expression of wound healing and stress-related proteins in keratoconus corneas</i> , Current Eye Research, 15 (11):1124-1131 (1996)		

antibiotic

03/23/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.